<![CDATA[Sonesitatug Vedotin Improves Overall Survival in CLDN18.2+ Gastric Cancer]]>
Phase 3positiveSonesitatug vedotinPositive
AI Analysis
Summary
Sonesitatug vedotin achieved positive Phase 3 results, meeting dual primary survival endpoints in the CLARITY-Gastric01 trial for CLDN18.2-positive gastric and gastroesophageal junction cancer.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Met dual primary survival endpoints in CLARITY-Gastric01 trial
Importance:8/10
Sentiment:
0.85
Phase 3gastric cancerCLDN18.2survival dataoncology
Related Companies
Read the original article
Published by Cancer Network on July 27, 2026 4:00 PM